Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

The IMCore of the UW Sensory Biology Center is pleased to announce the availability of an Illumina NextSeq 1000 sequencer. This equipment is purchased exclusively via an administrative supplement ...

Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

Work within a regulated sequencing workflow for developing diagnostic ... work in a research environment and use the full range of Illumina sequencing methods for a wide range of applications.

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in China, growing competitive threats, and the potential for Trump ...

Q4 2024 Management View CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted ...

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.